Home > Insider Trading > Filing (0001209191-14-067091)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
353569	Quidel Corp	QDEL	In Vitro & In Vivo Diagnostic Substances (2835)	942573850

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1077650	F Rodney Dammeyer	10165 Mckellar Court San Diego CA 92121		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2014-11-04	9,331	$9.93	13,237	No	4	M	Direct
Common Stock	Acquisiton	2014-11-04	9,331	$13.97	22,568	No	4	M	Direct
Common Stock	Disposition	2014-11-04	18,662	$27.80	3,906	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Non-Qual Stock Options	Disposition	2014-11-04	9,331	$0.00	9,331	$9.93
Common Stock	Non-Qual Stock Options	Disposition	2014-11-04	9,331	$0.00	9,331	$13.97

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2007-05-17	2016-05-17	No	4	M	Direct
0	2008-05-07	2017-05-07	No	4	M	Direct

Footnotes

In addition to the shares reported on this Form 4 as directly owned by the Reporting Person, 34,692 shares are held indirectly by the Dammeyer Family Trust. The Reporting Person disclaims all beneficial ownership of the shares owned by the Dammeyer Family Trust, except to the extent of his pecuniary interest, if any, and the inclusion of these shares in this report should not be deemed an admission of beneficial ownership of all of the reporting shares for purposes of Section 16 of or any other purpose.
All of the securities sold were sold under Rule 144 as a stock option exercise.
The weighted average purchase price for these transactions was $27.8014 per share, with a range of $27.69 to $27.97 per share. Upon request, the Reporting Person hereby undertakes to provide to staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder, the full information regarding the number of shares purchased at each separate price.